Lung cancer is the leading cause of cancer death worldwide. The epidermal growth factor receptor (EGFR) represents the main target for non-small cell lung cancer (NSCLC) therapy, as its overexpression or constitutive activation contributes to malignancy and correlates with poor prognosis. In this study, we silenced β1 integrin in human NSCLC A549 cells. The β1 integrin-silenced cells show a defective activation of the EGFR signaling cascade, leading to decreased in vitro proliferation, enhanced sensitivity to cisplatin and Gefitinib, impaired migration and invasive behavior. Moreover, β1 integrin silencing increases the amount of EGFR on the cell surface, suggesting that β1 integrin is required for efficient constitutive EGFR turnover at the cell membrane. Although the rate of EGF internalization and recycling is not affected in silenced cells, EGFR signaling is recovered only by expression of the Rab-coupling protein RCP, indicating that β1 integrin sustains the endocytic machinery required for EGFR signaling. Overall, these results show that β1 integrin is an essential regulator of EGFR signaling and tumorigenic properties of lung cancer cells, and that its silencing might represent an adjuvant approach to anti-EGFR therapy.Oncogene advance online publication, 11 April 2011; doi:10.1038/onc.2011.107.

β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells.

MORELLO, Virginia;CABODI, Sara;CAMACHO LEAL, MARIA del PILAR;REPETTO, DANIELE;VOLANTE, Marco;PAPOTTI, Mauro Giulio;TURCO, Emilia;DEFILIPPI, Paola
2011

Abstract

Lung cancer is the leading cause of cancer death worldwide. The epidermal growth factor receptor (EGFR) represents the main target for non-small cell lung cancer (NSCLC) therapy, as its overexpression or constitutive activation contributes to malignancy and correlates with poor prognosis. In this study, we silenced β1 integrin in human NSCLC A549 cells. The β1 integrin-silenced cells show a defective activation of the EGFR signaling cascade, leading to decreased in vitro proliferation, enhanced sensitivity to cisplatin and Gefitinib, impaired migration and invasive behavior. Moreover, β1 integrin silencing increases the amount of EGFR on the cell surface, suggesting that β1 integrin is required for efficient constitutive EGFR turnover at the cell membrane. Although the rate of EGF internalization and recycling is not affected in silenced cells, EGFR signaling is recovered only by expression of the Rab-coupling protein RCP, indicating that β1 integrin sustains the endocytic machinery required for EGFR signaling. Overall, these results show that β1 integrin is an essential regulator of EGFR signaling and tumorigenic properties of lung cancer cells, and that its silencing might represent an adjuvant approach to anti-EGFR therapy.Oncogene advance online publication, 11 April 2011; doi:10.1038/onc.2011.107.
30(39)
4087
4096
http://dx.doi.org/10.1038/onc.2011.107
http://www.nature.com/onc/journal/v30/n39/pdf/onc2011107a.pdf
EGFR; β1 integrin; lung cancer
Morello V; Cabodi S; Sigismund S; Camacho-Leal MP; Repetto D; Volante M; Papotti M; Turco E; Defilippi P
File in questo prodotto:
File Dimensione Formato  
Virginia.pdf

Accesso aperto

Tipo di file: POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione 1.3 MB
Formato Adobe PDF
1.3 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/89586
Citazioni
  • ???jsp.display-item.citation.pmc??? 62
  • Scopus 105
  • ???jsp.display-item.citation.isi??? 102
social impact